200 Summit Lake Drive
143 articles with FUJIFILM
Mawi DNA Technologies has signed a distribution agreement with FUJIFILM Wako Pure Chemical Corporation, a leader in the biomedical industry, to deliver Mawi’s iSWAB biosampling technologies to Japan.
Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has announced that it has entered into a new strategic partnership agreement with Fujifilm Corporation.
Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan®/Reeqonus™ for COVID-19 Patients
Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan ® /Reeqonus™ for COVID-19 Patients
Fujifilm Corporation, a global medical imaging device provider, announced its AI-powered product for analyzing chest X-ray 'CXR-AID' will be commercially available across Japan.
The new $550 million site in N.C. follows the advanced packaging plant in Ohio that will significantly expand the company’s manufacturing capacity in the U.S.
The investment made to build this end-to-end cell culture biopharmaceutical contract development and manufacturing organization facility clocked in at approximately $2 billion.
Fujifilm Selects North Carolina as the Location to Build the Largest Cell Culture Biopharmaceutical CDMO Facility in North America
Fujifilm to invest $2 Billion and create 725 jobs with its new state-of-the-art large-scale cell culture manufacturing facility in Holly Springs, North Carolina
FUJIFILM Cellular Dynamics and Sana Biotechnology Announce License Agreement for the Development of iPSC-Derived Cell Therapies
FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, announced today that Sana has been granted a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development of commercial cell therapies.
FUJIFILM Sonosite deploys new Point-of-Care Ultrasound Workflow Management Solution at Kaweah Delta Medical Center's Emergency Department
FUJIFILM Sonosite, Inc. , the world leader in point-of-care ultrasound solutions, announced today that Kaweah Delta Medical Center's Emergency Department has gone live with Sonosite Synchronicity™, a comprehensive point-of-care ultrasound (POCUS) workflow solution.
Fujifilm and the Center for Advanced Biological Innovation and Manufacturing Announce $76M in Funding for Manufacturing and Innovation Center
FUJIFILM Corporation (COO: Kenji Sukeno ) and the Center for Advanced Biological Innovation and Manufacturing (CABIM), today announced that it has secured $76 million in financing and signed a lease for a 40,000 square-foot site in Watertown, Massachusetts at The Arsenal on the Charles , owned and operated by Alexandria Real Estate Eq
Fujifilm to Invest Over 200 Billion yen (2 Billion USD) to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A.
FUJIFILM Corporation is making an investment of more than 200 Billion yen to establish a new large-scale cell culture production site in the United States to accelerate the growth of its biopharmaceutical contract development and manufacturing business.
Fujifilm to invest $40 Million to Establish a New State-of-the-Art Viral Vector and Advanced Therapy Process Development and Manufacturing Facility
Establishing a presence in Massachusetts within the academia and pharma communities to perform cutting-edge research and innovation in the field of advanced therapies.
Largest urology practice with 30+ locations and 90+ providers standardizes their practice with the Persona CT computed tomography system for advanced oncology treatment planning
Fujifilm Sonosite Receives FDA COVID-19 510(k) Clearance for Comprehensive Point-of-Care Ultrasound Portfolio
FUJIFILM Sonosite , Inc., specialists in developing cutting-edge point-of-care ultrasound (POCUS) solutions, and part of the larger Fujifilm Healthcare portfolio, today announced that the company has received 510(k) Clearance from the U.S. Food & Drug Administration (FDA) for the company's entire POCUS portfolio to sup
FUJIFILM Sonosite Launches New Point-Of-Care Ultrasound System With Adaptable Form Factor, Embedded Workflow, And The Most Advanced Image Clarity Sonosite Has Ever Offered
FUJIFILM Sonosite, Inc. , specialists in developing cutting-edge point-of-care ultrasound (POCUS) solutions, and part of the larger Fujifilm Healthcare portfolio, has announced the launch of the new Sonosite PX ultrasound system. Sonosite PX is the next generation in Sonosite POCUS, with the most advanced image clarity ever seen in
Dr. Reddy’s Partners with FUJIFILM and Global Response Aid for Avigan® (favipiravir), a Potential Treatment of COVID-19
Dr. Reddy's Laboratories Ltd. announces partnering with FUJIFILM Corporation through FUJIFILM Toyama Chemical Co. Ltd. and Global Response Aid for the development, manufacture and sales of Avigan® Tablets, a potential treatment of COVID-19.
Fujifilm to invest 100 billion yen (928 million USD) to expand its large scale biologics production facility in Denmark
FUJIFILM Corporation will make a major capital investment of approximately 100 billion yen in the Denmark site of FUJIFILM Diosynth Biotechnologies, a leading contract development and manufacturing organization for biologics and advanced therapies.
Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks
Appili Therapeutics Inc., a biopharmaceutical company focused on anti-infective drug development, announced that Health Canada provided regulatory clearance for Appili’s Phase 2 study evaluating FUJIFILM Toyama Chemical’s favipiravir as a preventative measure against COVID-19 outbreaks.
Fabian, President and COO of FUJIFILM Sonosite, Inc., applauds AdvaMed for its leadership in times of health crisis
Appili Therapeutics Submits CTA with Health Canada to Sponsor Prophylactic Phase 2 Clinical Trial Evaluating FUJIFILM Toyama Chemical’s Favipiravir as a Preventative Measure Against COVID-19 in Canadian Long-Term Care Facilities
First clinical program in the world designed to assess the use of favipiravir for COVID-19 as prophylaxis for outbreak control; antiviral drug has shown early efficacy against COVID-19